Financial Performance And ExpectationsThe company's $16.1M in 2Q revenues were below Street expectations of $24M, with management anticipating a further drop in total revenue in the following quarter.
Financial Stability And Dilution RiskAmending the Hercules agreement and pushing milestones into 2025, along with the requirement of near-term financing, could result in near-term dilution, placing pressure on the company's financial stability.
Product Safety ConcernsSeven of the 67 patients enrolled in the various studies on Skysona developed hematologic cancers, a risk that the FDA has flagged with a blackbox warning, potentially hindering further uptake of the therapy.